Oncotarget

Research Papers:

Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia

Ayman A.M. Alameen, Carolina Simioni, Alberto M. Martelli, Giorgio Zauli, Simona Ultimo, James A. McCubrey, Arianna Gonelli, Giorgia Marisi, Paola Ulivi, Silvano Capitani and Luca M. Neri _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:55690-55703. https://doi.org/10.18632/oncotarget.10984

Metrics: PDF 1847 views  |   HTML 2118 views  |   ?  


Abstract

Ayman A.M. Alameen1,2,*, Carolina Simioni1,*, Alberto M. Martelli3, Giorgio Zauli1, Simona Ultimo1, James A. McCubrey4, Arianna Gonelli1, Giorgia Marisi5, Paola Ulivi5, Silvano Capitani1,6, Luca M. Neri1

1Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy

2Department of Chemical Pathology, Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan

3Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

4Department of Microbiology & Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA

5Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy

6LTTA Center, University of Ferrara, Ferrara, Italy

*These authors have contributed equally to this work

Correspondence to:

Luca M. Neri, email: luca.neri@unife.it

Silvano Capitani, email: silvano.capitani@unife.it

Keywords: T lymphocytes, PI3K/Akt/mTOR signaling, T-acute lymphoblastic leukemia, targeted therapies, autophagy

Received: May 05, 2016     Accepted: July 11, 2016     Published: August 1, 2016

ABSTRACT

An attractive molecular target for novel anti-cancer therapies is the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway which is commonly deregulated in many types of cancer. Nevertheless, the effects of PI3K/Akt/mTOR inhibitors on T lymphocytes, a key component of immune responses, have been seldom explored. In this study we investigated the effects on human CD4+ T-cells of a panel of PI3K/Akt/mTOR inhibitors: BGT226, Torin-2, MK-2206, and ZSTK474. We also assessed their efficacy against two acute leukemia T cell lines. T lymphocytes were stimulated with phytohemagglutinin. Inhibitor effects on cell cycle and apoptosis were analyzed by flow cytometry, while cytotoxicity was assessed by MTT assays. In addition, the activation status of the pathway as well as induction of autophagy were analyzed by Western blotting.

Quiescent healthy T lymphocytes were unaffected by the drugs whereas mitogen-stimulated lymphocytes as well as leukemic cell lines displayed a cell cycle block, caspase-dependent apoptosis, and dephosphorylation of key components of the signaling pathway. Autophagy was also induced in proliferating lymphocytes and in JURKAT and MOLT-4 cell lines. When autophagy was inhibited by 3-methyladenine or Bafilomycin A1, drug cytotoxicity was increased, indicating that autophagy is a protective mechanism.

Therefore, our findings suggest that PI3K/Akt/mTOR inhibitors preserve lymphocyte viability. This is a valuable result to be taken into account when selecting drugs for targeted cancer therapy in order to minimize detrimental effects on immune function.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10984